Results 191 to 200 of about 9,155 (253)

Successful Revascularization of Chronic Total Occlusions in Patients With Chronic Thromboembolic Pulmonary Disease

open access: yesCatheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2323-2334, June 1, 2026.
ABSTRACT Background Chronic thromboembolic pulmonary disease (CTEPD) leads to chronic total occlusions (CTOs) of the pulmonary arteries in a minority of patients. Treatment of CTOs with balloon pulmonary angioplasty (BPA) may substantially improve patient hemodynamics but presents unique technical challenges and has previously been associated with a ...
Elliot J. Stein   +4 more
wiley   +1 more source

Safely Treating a Pulmonary Embolism in a Patient With Hereditary Hemorrhagic Telangiectasia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Hereditary Hemorrhagic Telangiectasia (HHT) is a rare autosomal dominant bleeding disorder. The incidence of venous thromboembolisms among HHT patients is significantly greater than the general population. However, providing therapeutic anticoagulation in patients with an increased propensity for bleeding creates a clinical dilemma.
Christina Carfagnini, Manasa Kandula
wiley   +1 more source

Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1‐Related Noonan Syndrome (p.Ser257Leu): A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT This case describes a female infant with RAF1‐related Noonan syndrome who developed severe hypertrophic obstructive cardiomyopathy, pulmonary hypertension, and cardiorespiratory failure that responded to trametinib treatment but ultimately progressed to death following dose tapering and discontinuation of therapy. To the best of our knowledge,
C. Noah Nilsson   +8 more
wiley   +1 more source

Paradoxical Rise in Pulmonary Artery Pressure Following Successful Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT A paradoxical rise in pulmonary artery pressure on follow‐up echocardiography after successful mavacamten therapy for obstructive hypertrophic cardiomyopathy (oHCM) prompted right heart catheterization, which demonstrated combined pre‐ and post‐capillary pulmonary hypertension and guided the decision to continue mavacamten while withholding ...
Mengdian Zhang
wiley   +1 more source

Evaluate the Prognostic Value of serumγKlotho on Long‐Term Prognosis of Patients With Multivessel Coronary Artery Disease and Establish a Prognostic Model

open access: yesClinical Cardiology, Volume 49, Issue 6, June 2026.
Higher serum γKlotho level correlated with the poor prognosis of MVD patients, our predictive model exhibited better predictive ability and clinical usefulness. ABSTRACT Objective This study was aimed at analyzing the correlation of serum γKlotho with the long‐term prognosis of multivessel coronary artery disease (MVD) and develop a predictive model to
Tuersunjiang Naman   +8 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1494-1502, June 2026.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz   +15 more
wiley   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, Volume 2, Issue 2, June 2026.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

Acute Pericardial Effusion After Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

open access: yesJournal of Arrhythmia, Volume 42, Issue 3, June 2026.
This study reports a 25.2% incidence of acute pericardial effusion following vein of Marshall ethanol infusion for persistent atrial fibrillation. The extent of the resulting low‐voltage area was identified as an independent predictor of pericardial effusion, reflecting the magnitude of chemical injury.
Hualong Li   +4 more
wiley   +1 more source

Feasibility and Safety of High‐Power Settings for Electrical Isolation of the Superior Vena Cava Using a Catheter Capable of Local Impedance and Contact Force Monitoring

open access: yesJournal of Arrhythmia, Volume 42, Issue 3, June 2026.
High‐power superior vena cava isolation using a contact force– and local impedance–sensing catheter achieved safe and consistent first‐pass isolation. Local impedance decreased more rapidly than generator impedance, accurately reflecting effective lesion formation and enabling reliable real‐time assessment in thin SVC myocardium.
Daisuke Kawano   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy